Colin Ross is an Assistant Professor, at UBC, Faculty of Pharmaceutical Sciences and is responsible for CPNDS genomic analyses. His key area of research is to understand why some patients respond positively to certain medications, while a small fraction of similar patients develop serious, debilitating or even life-threatening adverse reactions to the same medications.
Rod Rassekh is a pediatric oncologist at BC Children’s Hospital. His main research interest is identifying risk factors for adverse events due to chemotherapy. As a doctor treating children with cancer, he currently has to use chemotherapy which come with major side effects, many of which are life threatening. His goal is to make chemotherapy safer for kids by identifying genetic risk factors that may help him personalize treatment for children being diagnosed with cancer.
Amit Bhavsar is a Research Associate, at UBC in the Department of Pediatrics, and is responsible for CPNDS functional validation studies. His goal is to understand the biology underlying associations between genetic variation and adverse drug reactions. He believes that we can harness this knowledge to develop rational ways of preventing ADRs, and also to migrate CPNDS discoveries into the clinic.
Folefac Aminkeng is a Research Associate, at UBC in the Department of Human Genetics & Pediatrics. His research interests are on the pharmacogenomics of adverse drug reactions in oncology and on the pharmacogenomic pharmacoethnicity in world-wide populations, including aboriginal populations in North America.
Michael Rieder is a Professor, Departments of Medicine/Dentistry, Pediatrics, and Physiology/Pharmacology at the University of Western Ontario and CIHR-GSK Chair in Paediatric Clinical Pharmacology at the Schulich School of Medicine Dentistry. His principal area of research is adverse drug reactions, with a special focus on mechanistic studies of hypersensitivity ADRs including the role of reactive drug metabolites in ADRs.
Régis Vaillancourt is currently the Director of Pharmacy at the Children’s Hospital of Eastern Ontario. In order to maintain well-rounded clinical pharmacy skills, Dr Vaillancourt provides clinical pediatric pharmacy support to Palliative and Chronic Pain services.
Gideon Koren is the founder and director of the Motherisk Program and a professor of Pediatrics, pharmacology, pharmacy and medical genetics at the University of Toronto. He is a staff pediatrician at The Hospital for Sick Children in Toronto and the Ivey Chair in Molecular Toxicology, the University of Western Ontario. He is author of 1200 peer reviewed scientific papers and 15 medical books. His principal areas of research and practice are adverse effects of drugs and chemicals during human development, including pregnancy and childhood.
Stuart MacLeod is the former Executive Director, Child & Family Research Institute, Professor, Pediatrics and Associate Dean (Research), Faculty of Medicine, University of British Columbia, and Vice President Academic Liaison & Research Coordination for the Provincial Health Services Authority. Dr. MacLeod’s scientific interests are in improved understanding of the determinants of drug disposition and action, particularly in children and women. His concerns embrace the multitude of factors that influence optimal therapeutic drug use and the use of research findings to inform clinical and public policy. Internationally, Dr. MacLeod has coordinated several projects and taught in Africa. He has worked with international agencies and institutions including CIDA, IDRC, WHO and the Rockefeller Foundation.
David W. Johnson is a pediatric emegency physician at the Alberta Children’s Hospital, a researcher, medical toxicologist and a professor of Pediatrics and Physiology & Pharmacology with the Faculty of Medicine at the University of Calgary. Dr. Johnson is also Theme Director for the Alberta Children’s Hospital Research Institute (ACHRI), and working to broadly improve child health outcomes by developing and implementing clinical pathways for common childhood diseases. His research and interests are primarily focused on the management of common childhood respiratory emergencies, and ensuring primary health care professionals utilize ‘best evidence’ in managing these diseases.
Nicholas Honcharik Pharm. D., FCSHP, Dr. Nicholas Honcharik is currently Regional Pharmacy Manager, Professional Practice Development, Clinical Assistant Professor, Faculty of Pharmacy, University of Manitoba and Site Investigator/Coordinator for CPNDS at the Health Sciences Centre, Winnipeg. Research interests currently include critical care, medication safety and pharmacy practice.
Shinya Ito is a Professor at the University of Toronto and Head of the Division of Clinical Pharmacology & Toxicology in the Department of Paediatrics at the Hospital for Sick Children in Toronto. His key areas of research interests are 1) Breastfeeding and drug safety 2) Paediatric pharmacogenomics and 3) Drug transporter pharmacology.
Jean François Bussières B Pharm MSc MBA FCSHP, is Director of Pharmacy Department and Pharmacy Practice Research Unit at CHU Sainte-Justine and Professor at Faculty of Pharmacy, Université de Montréal. His research interests includes the evaluation of pharmacy practices, pharmacotherapy in mother-child, legislation, ethics and drug-use process technologies. He blogs every week on http://urppchusj.wordpress.com.
Denis Lebel is a pharmacist at CHU Sainte-Justine in Montréal, and is part of “Unité de Recherche en Pratiques Pharmaceutiques. His main research focus is evaluation of technology and safe medication use. He finds it hard to tell parents the reason for their child’s adverse drug reaction is unknown. Identification of genetic risk factors will help explain those reactions and contribute to prevention.
Robert L. Poole is the Director of Pharmacy at Lucile Packard Children’s Hospital at Stanford and Clinical Professor of Pharmacy at the University of California, San Francisco, School of Pharmacy. Areas of research include Adverse Drug Reactions in Children, Prevention of Medication Errors and Pediatric Parenteral Nutrition.
Geoffrey Liu is the Alan B. Brown Chair in Molecular Genomics and the Cancer Care Ontario Chair in Experimental Therapeutics and Population Studies. He is the Director of the Applied Molecular Profiling Pharmacogenomic Epidemiologic Laboratory at Princess Margaret Hospital and Ontario Cancer Institute. He is the co-Director or the Ontario Patient Reported Outcomes of Symptoms and Toxicity (On-PROST) Applied Clinical Research Unit, the Co-Director of the COMBEL (Cancer Outcomes, Medicine, Biostatistics, Epidemiology and Laboratory) Training Initiative at Princess Margaret Hospital, and Associate Professor of Epidemiology, Dalla Lana School of Public Health, and the Departments of Medicine and Medical Biophysics at the University of Toronto. His research focus is on the pharmacogenomic epidemiology of solid cancers, pharmacogenomic biomarker discovery and validation through clinical trial and population studies, and pharmacogenomic knowledge translation.
Marie-Pierre Dubé heads the Statistical Genetics Research Group at the Montreal Heart Institute and is the CPNDS statistical lead. Dr. Dubé specializes in the development of statistical genetic methods for the analysis of large genotype datasets, particularly in pharmacogenomics.
Paul Rogers is a Clinical Professor and Head of the Division of Pediatric Hematology/Oncology/Bone Marrow Transplantation, British Columbia Children’s Hospital. Dr. Rogers is key to CPNDS recruitment efforts in pediatric oncology in BC, and across Canada through the C17 research network.
Mara Medeiros is Professor, Department of Pharmacology, School of Medicine, National Autonomous University of Mexico, researcher and head of the Nephrology and Bone Mineral Metabolism Research Laboratory at the Federico Gomez Children’s Hospital in Mexico City. Her principal areas of interest are drug induced nephrotoxicity, immunosuppressant pharmacokinetics-pharmacogenomics, biomarkers of graft rejection and renal function.